

# Proof of principle for the use of the T cell ELISpot in clinical trial settings

*Optimization strategies and considerations*



**Julian J. Freen-van Heeren, PhD.**

Scientist Immunomonitoring Services

[j.freenvanheeren@sanquin.nl](mailto:j.freenvanheeren@sanquin.nl)

[immunomonitoring@sanquin.nl](mailto:immunomonitoring@sanquin.nl)




**Sanquin**

*a not for profit organization*

# ELISpot assays

- The enzyme-linked immunospot (ELISpot) assay is a highly sensitive test to determine the frequency of antigen-specific cells by determining effector molecule secretion at a single cell level
- Can be used to detect singular production of a single effector molecule of interest (ELISpot) or a combination of multiple effector molecules (FluoroSpot)
  - IFN- $\gamma$ , granzyme B, perforin, TNF- $\alpha$  – cytotoxic CD8<sup>+</sup> T cells
  - IL-2, IL-10, TNF- $\alpha$  – helper CD4<sup>+</sup> T cells
  - Antibody (and isotypes) – B cells
- Highly sensitive and high throughput
- Requires fewer cells than typical approaches (i.e. ELISA or flow cytometric readout of intracellular cytokine production)

# How do ELISpots work?




# Variables that can influence ELISpot results

- Before assay
  - Donor variation
  - Quality of cells and cell source
    - *Thawing and optional rest steps*
- Stimulation-related
  - Background
  - Cell numbers
  - Medium used
    - *Use of serum*
  - Number of replicates
  - Type of stimulation and positive control(s)
- Measurement-related
  - Spot contrast/intensity, size and shape
  - For FluoroSpot: laser voltage and maintenance (when applicable)


# Variables that can influence ELISpot results

- Before assay
  - Donor variation
  - Quality of cells and cell source
    - *Thawing and optional rest steps*
- Stimulation-related
  - Background
  - Cell numbers
  - Medium used
    - *Use of serum*
  - Number of replicates
  - Type of stimulation and positive control(s)
- Measurement-related
  - Spot contrast/intensity, size and shape
  - For FluoroSpot: laser voltage and maintenance (when applicable)

# Influence of cell numbers, background and donor variation



# Influence of medium choice and serum addition





Cells were stimulated in triplicate with 1  $\mu$ M CEFT overnight, and IFN- $\gamma$  producing cells were assessed by ELISpot.

\* indicates significantly different compared to non-stimulated AIM-V ( $P < 0.05$ )



\*/\*\* indicates significantly different compared to CEFT-stimulated AIM-V ( $P < 0.05 / < 0.01$ )

# FluoroSpot to determine multiple parameters



Cells were stimulated in triplicate with 1  $\mu$ M peptide overnight, and IFN- $\gamma$  producing cells were assessed by ELISpot.

# Using ELISpot to determine SARS-CoV-2 cellular immunity



Cells from healthy donors ( $n=2$ ) or ex-COVID patients ( $n=5$ ) (both self reported) were stimulated in triplicate with 1  $\mu\text{g}/\text{mL}$  SARS-CoV-2 nucleocapsid and spike peptide pools, after which IFN- $\gamma$  producing cells were assessed via ELISpot. CEFT was used as a positive control.

# Conclusion

- Many variables can be of influence on ELISpot results, therefore qualified personnel and standardization are of importance.
- ELISpot assays are useful tools for high-throughput screening of patient/donor samples, and can be of use in many fields of research (vaccine development, epidemiology, auto-immune diseases, etc).

# Acknowledgements

- Sanquin's Immunomonitoring team:
  - David Cobeta Lopez
  - Feresthe Rezai
  - Irma Rensink
  - Suzanne Lissenberg-Thunissen
  - Dominique Kivits
  - Sinéad Loughheed
  - Rianne Opstelten
  - Annelies Turksma
  - Anja ten Brinke
  - Annick de Vries

## Special thanks to

- Healthy blood bank donors
- Ex-COVID donors

